The TAILORx results provide definitive answers

"Adjuvant chemotherapy may now be guided with an unprecedented level of evidence and precision" said lead author Joseph A. Sparano, MD. "The 21-gene assay ... [can] identify the 70% of women with no chemotherapy benefit, and the others where chemotherapy may be life-saving." Know with confidence who will benefit from chemotherapy and who will not.^1-4

The largest randomized adjuvant breast cancer trial ever conducted, the Trial Assigning IndividuaLized Options for Treatment (Rx) (TAILORx) was independently led by ECOG-ACRIN Cancer Research Group with sponsorship from the National Cancer Institute.

As presented at ASCO 2019, a new analysis of TAILORx confirms the original, definitive conclusions reported previously with additional detail on clinical risk, focusing on patients with early-stage breast cancer who are age 50 years or younger.

As presented at ESMO 2019, a new, secondary analysis of TAILORx, highlighted clinical outcomes in patients with a Recurrence Score result of 26‐100. This new analysis reinforces the definitive results of TAILORx, that only the Oncotype DX Breast Recurrence Score test identifies patients who will and will not benefit from chemotherapy.

See the new analysis on JAMA Oncology

Participating cancer research groups included the Alliance for Clinical Trials in Oncology, NCIC-Clinical Trials Group, NRG Oncology, and SWOG.

In early stage ER+, HER2-, N0 breast cancer, who benefits from chemotherapy?

No more “Intermediate” Recurrence Score results

• No statistically significant difference in invasive disease-free survival was found among patients with Recurrence Score (RS) results 11–25, proving that they do not benefit from chemotherapy²
• TAILORx expanded on previous data, confirming excellent outcomes at 9 years for patients with RS results 0–25 treated with endocrine therapy alone^1,2
• For RS results 26–100, there was a significantly higher event rate despite treatment with adjuvant chemotherapy²

*Driven largely by the higher likelihood of having an event in the cohort with an RS 26–100.

Clarity on which patients can be spared chemotherapy

• No statistically significant difference between treatment groups for freedom from distant recurrence at 9 years²
• TAILORx showed that patients with Recurrence Score results 11–25 can be spared chemotherapy²

Subset analysis in patients aged 50 or younger

In an exploratory analysis, TAILORx showed a chemotherapy benefit for early breast cancer patients aged 50 or younger with RS scores of 16–25. This subgroup represents about 8% of patients.⁵